Acer Therapeutics to Present at UBS Global Healthcare Conference
07. Mai 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious...
Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data
16. April 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
CORRECTING and REPLACING -- Acer Therapeutics to Participate in Upcoming Investor Conferences
13. März 2019 11:17 ET
|
Acer Therapeutics Inc.
In a release issued earlier today by Acer Therapeutics Inc. (Nasdaq: ACER), please note in the table for the Roth Capital Partners 31st Annual Growth Stock Conference, a time of 3:30 pm Pacific Time...
Acer Therapeutics to Participate in Upcoming Investor Conferences
13. März 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
07. März 2019 16:01 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces In-license of Osanetant from Sanofi
02. Januar 2019 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO™ for the Treatment of vEDS
26. Dezember 2018 08:30 ET
|
Acer Therapeutics Inc.
Acer continues progress toward goal of commercializing EDSIVO™ NEWTON, Mass., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the...
Acer Therapeutics Appoints Salma Jutt as Chief Commercial Officer
17. Dezember 2018 08:30 ET
|
Acer Therapeutics Inc.
Seasoned veteran brings two decades of commercial experience to Acer Acer continues to execute on activities towards its goal of commercializing EDSIVO™ NEWTON, Mass., Dec. 17, 2018 (GLOBE...
Acer Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
09. November 2018 16:01 ET
|
Acer Therapeutics Inc.
Acer continues to progress towards goal of commercializing EDSIVO™ Company appoints VPs of Corporate Development and IT & Database Administrator NEWTON, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE)...
Acer Therapeutics to Present at the Evercore ISI HealthConX Conference
08. November 2018 08:30 ET
|
Acer Therapeutics Inc.
NEWTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...